Literature DB >> 19923479

Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide.

Pamela Chedore1, Lina Bertucci, Joyce Wolfe, Meenu Sharma, Frances Jamieson.   

Abstract

During susceptibility testing of 743 isolates of Mycobacterium tuberculosis to pyrazinamide (PZA) using the Bactec 960 system, 57 (7.7%) isolates showed PZA resistance. Repeat testing of resistant isolates with the Bactec 460 reference method confirmed 33 (4.4%) of these isolates as resistant, and 24 (3.2%) were susceptible. Erroneous results for resistance with the Bactec 960 were confirmed by testing the 24 discordant isolates for pyrazinamidase and mutations in the pncA gene.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19923479      PMCID： PMC2812260          DOI： 10.1128/JCM.01775-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  11 in total

1.  Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis.

Authors:  M Mestdagh; P A Fonteyne; L Realini; R Rossau; G Jannes; W Mijs; K A De Smet; F Portaels; E Van den Eeckhout
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

2.  Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis.

Authors:  A P Davies; O J Billington; T D McHugh; D A Mitchison; S H Gillespie
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

3.  Multicenter evaluation of the fully automated Bactec MGIT 960 system for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide: comparison with the radiometric Bactec 460TB system.

Authors:  Fanourios Kontos; Stavroula Nicolaou; Christos Kostopoulos; Zoe Gitti; Efthymia Petinaki; Maria Maniati; Spyridoula Anagnostou; Aikaterini Raftopoulou; Panagiota Papageorgiou; Aggeliki Scrioubellou; Ioannis Tselentis; Antonios N Maniatis
Journal:  J Microbiol Methods       Date:  2003-10       Impact factor: 2.363

4.  Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.

Authors:  Ying Zhang; Sallie Permar; Zhonghe Sun
Journal:  J Med Microbiol       Date:  2002-01       Impact factor: 2.472

5.  Simple pyrazinamidase and urease tests for routine identification of mycobacteria.

Authors:  L G Wayne
Journal:  Am Rev Respir Dis       Date:  1974-01

6.  Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system.

Authors:  Gaby E Pfyffer; Frantiska Palicova; Sabine Rüsch-Gerdes
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

7.  Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus.

Authors:  A Scorpio; Y Zhang
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

Review 8.  Laboratory diagnostic aspects of drug resistant tuberculosis.

Authors:  Linda M Parsons; Akos Somoskövi; Richard Urbanczik; Max Salfinger
Journal:  Front Biosci       Date:  2004-09-01

9.  Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide, streptomycin, isoniazid, rifampin, and ethambutol and comparison with the radiometric BACTEC 460TB method.

Authors:  Claudio Scarparo; Paolo Ricordi; Giuliana Ruggiero; Paola Piccoli
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

10.  Evaluation of BACTEC MGIT 960 PZA medium for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide (PZA): compared with the results of pyrazinamidase assay and Kyokuto PZA test.

Authors:  Akio Aono; Kazue Hirano; Sonomi Hamasaki; Chiyoji Abe
Journal:  Diagn Microbiol Infect Dis       Date:  2002-12       Impact factor: 2.803
View more
  50 in total

1.  Drug resistance patterns in 111 cases of drug-resistant tuberculosis spine.

Authors:  Kapil Mohan; Saurabh Rawall; Uday M Pawar; Meeta Sadani; Premik Nagad; Amita Nene; Abhay Nene
Journal:  Eur Spine J       Date:  2012-01-20       Impact factor: 3.134

2.  Role of pncA and rpsA gene sequencing in detection of pyrazinamide resistance in Mycobacterium tuberculosis isolates from southern China.

Authors:  Yaoju Tan; Zuqiong Hu; Tianyu Zhang; Xingshan Cai; Haobin Kuang; Yanwen Liu; Junyu Chen; Feng Yang; Ke Zhang; Shouyong Tan; Yanlin Zhao
Journal:  J Clin Microbiol       Date:  2013-10-16       Impact factor: 5.948

3.  Pyrazinamide Is Active against Mycobacterium tuberculosis Cultures at Neutral pH and Low Temperature.

Authors:  Alice L den Hertog; Sandra Menting; Richard Pfeltz; Matthew Warns; Salman H Siddiqi; Richard M Anthony
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

Review 4.  Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance.

Authors:  Claudio U Köser; Silke Feuerriegel; David K Summers; John A C Archer; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

5.  Comparison and development of pyrazinamide susceptibility testing methods for tuberculosis in Thailand.

Authors:  Suporn Foongladda; Wiphat Klayut; Suporn Pholwat; Eric Houpt
Journal:  Diagn Microbiol Infect Dis       Date:  2015-07-17       Impact factor: 2.803

6.  Eligibility for a Shorter Treatment Regimen for Multidrug-resistant Tuberculosis in the United States, 2011-2016.

Authors:  Clarisse A Tsang; Neha Shah; Lori R Armstrong; Suzanne M Marks
Journal:  Clin Infect Dis       Date:  2020-02-14       Impact factor: 9.079

7.  Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibility.

Authors:  Elizabeth M Streicher; Kashmeel Maharaj; Talita York; Carel Van Heerden; Marinus Barnard; Andreas Diacon; Carl M Mendel; Marlein E Bosman; Juli A Hepple; Alexander S Pym; Robin M Warren; Paul D van Helden
Journal:  J Clin Microbiol       Date:  2014-08-27       Impact factor: 5.948

8.  Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Zhejiang, China.

Authors:  Qiang Xia; Li-Li Zhao; Feng Li; Yu-Mei Fan; Yuan-Yuan Chen; Bei-Bei Wu; Zheng-Wei Liu; Ai-Zhen Pan; Min Zhu
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

9.  Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.

Authors:  J Werngren; E Sturegård; P Juréen; K Ängeby; S Hoffner; T Schön
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

10.  Improved Bactec MGIT 960 Pyrazinamide Test Decreases Detection of False Mycobacterium tuberculosis Pyrazinamide Resistance.

Authors:  Alessandro Mustazzolu; Angelo Iacobino; Federico Giannoni; Claudio Piersimoni; Lanfranco Fattorini
Journal:  J Clin Microbiol       Date:  2017-09-13       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.